

Case Report

Sclerosing Cholangitis as Immune-Related Adverse Event Caused by Nivolumab and Ipilimumab Therapy

Shiho Katsue¹, Kenta Nakamura^{1*}, Rika Suzuki¹, Tatsuya Nihei¹, Yuko Takazawa¹, Toshikazu Omodaka¹, Yukiko Kiniwa¹, Shun-ichi Wakabayashi², Tomoo Yamazaki² and Ryuhei Okuyama¹

¹Department of Dermatology, Shinshu University School of Medicine, Japan

²Department of Gastroenterology and Hepatology, Shinshu University School of Medicine, Japan

***Corresponding author**

Kenta Nakamura, Department of Dermatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan, Tel: +81263372647; Fax: +81263372646; Email: kenta1983@shinshu-u.ac.jp

Submitted: 08 February 2021

Accepted: 28 February 2021

Published: 02 March 2021

ISSN: 2373-9371

Copyright

© 2021 Katsue S, et al.

OPEN ACCESS**Keywords**

- Sclerosing Cholangitis
- Immune-related adverse event
- Nivolumab
- Ipilimumab

Abstract

Immune checkpoint inhibitors (ICIs) cause several immune-related adverse events (irAEs); however, few studies have described sclerosing cholangitis (SC) and its therapeutics.

INTRODUCTION

We herein report a patient with SC that was associated with nivolumab and ipilimumab combination therapy for advanced melanoma.

CASE PRESENTATION

A 62-year-old Japanese man had primary oral melanoma with bilateral cervical lymph node metastases. Nivolumab and ipilimumab were initiated after proton therapy. Diarrhea and colitis (grade 2) occurred after two courses of the treatment. These symptoms improved after administering 1 mg/kg/day of prednisolone (PSL), which was reduced to 10 mg/day over 2 months. No relapse of irAEs occurred; therefore, nivolumab and ipilimumab were resumed. Two weeks after the fourth course of treatment, nausea (grade 2) occurred. Subsequently, 1 month later, hepatic dysfunction developed with the following enzyme levels: aspartate aminotransferase, 81 U/L (normal range 13-30); alanine aminotransferase, 130 U/L (10-42); γ -glutamyl transpeptidase, 514 U/L (13-64); and alkaline phosphatase, 1163 U/L (106-322). Biopsied liver showed infiltration of neutrophils and monocytes around the bile ducts (Figure 1a). Magnetic resonance imaging (MRI) showed peripheral-dominant dilatation of the intrahepatic bile ducts without occlusion (Figure 1b). The patient was diagnosed with SC associated with nivolumab and ipilimumab combination therapy. PSL was initiated at 1 mg/kg/day. However, hepatic dysfunction did not sufficiently improve. Two weeks later, mycophenolate mofetil (MMF) at 2 g/day and ursodeoxycholic acid (UDCA) were added to the treatment regimen followed by increased amount of PSL at 2 mg/

kg/day. Furthermore, intravenous methylprednisolone (1000 mg/day) was administered for 3 days, and the increase in bile duct enzymes stopped. Inflammatory cytokine levels partially reduced after increasing PSL with MMF/UDCA. The levels further reduced after methylprednisolone administration (Figure 1c), which was parallel to the improvement in bile duct enzymes. Although the bile duct enzymes were not completely normalized, PSL was gradually tapered off to 0.4 mg/kg/day together with MMF discontinuation.

DISCUSSION

ICI-induced SC is a rare irAE and its diagnostic criteria and therapeutics have not been established [1,2]. Recently, clinical characteristics of ICI-induced SC have been reported [3]. In ICI-induced SC, men are affected twice as often as women. Abdominal pain and discomfort occasionally occurs, and bile duct enzyme levels are remarkably increased compared to the liver enzymes. Intrahepatic bile duct dilatation without occlusion and infiltration of CD8⁺ T cells in and around the bile ducts are frequently observed [3,4]. Furthermore, ICI-induced SC does not respond well to corticosteroids. In our analysis, inflammatory cytokine levels increased in ICI-induced SC and the cytokine levels remarkably decreased after steroid pulse therapy, suggesting the significance of immunosuppression for the treatment. Corticosteroids are not sufficiently effective in ICI-induced SC; therefore, we need to clarify the inflammatory mechanism for an appropriate treatment. In addition, UDCA may be useful in reducing the onset of ICI-induced SC although it does not effectively improve SC after the onset [5].




Figure 1 (a) Histopathological features. Liver biopsy shows neutrophilic and monocytic infiltration around the bile duct (hematoxylin-eosin staining). (b) Imaging study. MRI shows peripheral-dominant dilatation of the intrahepatic bile duct without occlusion. Dilatation is absent in common bile duct and gallbladder. (c) Changes in inflammatory cytokine levels. Treatment with prednisolone (PSL) at 2 mg/kg/day and mycophenolate mofetil (MMF)/ ursodeoxycholic acid (UDCA) partially decreased serum levels of interleukin-1a (IL-1a), interleukin-6 (IL-6), and tumor necrosis factor- α (TNF- α). The levels were further decreased after a 3-day treatment of methylprednisolone (mPSL).

REFERENCES

- Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. *Ann Oncol*. 2017; 28: 671-72.
- Kawakami H, Tanizaki J, Tanaka K. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. *Invest New Drugs*. 2017; 35: 529-536.
- Takumi O, Yohei T, Taro Y, Hamamoto W, Sakamoto Y, Koda H, et al. HLH-2004: Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. *World J Gastroenterol*. 2020; 26: 353-365.
- Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. *Semin Diagn Pathol*. 2019; 36: 434-440.
- Zhu GQ, Shi KQ, Huang GQ, Wang LR, Lin YQ, Braddock M, et al. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. *Oncotarget*. 2015; 6: 26757-26769.

Cite this article

Katsui S, Nakamura K, Suzuki R, Nihei T, Takazawa Y, et al. (2021) Sclerosing Cholangitis as Immune-Related Adverse Event Caused by Nivolumab and Ipilimumab Therapy. *J Dermatolog Clin Res* 9(1): 1139.